Prolonged complete response after treatment withdrawal in HER2-overexpressed, hormone receptor-negative breast cancer with liver metastases: the prospect of disappearance of an incurable disease-Reference-Cited by-同舟云学术

Prolonged complete response after treatment withdrawal in HER2-overexpressed, hormone receptor-negative breast cancer with liver metastases: the prospect of disappearance of an incurable disease

Published:2014-09-22 Issue:1 Volume:14 Page:
ISSN:1471-2407
Container-title:BMC Cancer
language:en
Short-container-title:BMC Cancer

Author:

Viel Erika,Arbion Flavie,Barbe Catherine,Bougnoux Philippe

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Oncology

Link

http://link.springer.com/content/pdf/10.1186/1471-2407-14-690.pdf

Reference16 articles.

1. Kobayashi T, Ichiba T, Sakuyama T: Possible clinical cure of metastatic breast cancer: lessons from our 30-year experience with oligometastatic breast cancer patients and literature review. Breast Cancer. 2012, 19: 218-237. 10.1007/s12282-012-0347-0.

2. Park YH, Jung KH, Im SA: Phase III, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as first-line chemotherapy: KCSG-BR07-02. J Clin Oncol. 2013, 31: 1732-1739. 10.1200/JCO.2012.45.2490.

3. Tawfik H, Rostom Y, Elghazaly H: All-oral combination of vinorelbine and capecitabine as first-line treatment in HER2/Neu-negative metastatic breast cancer. Cancer Chemother Pharmacol. 2013, 71: 913-919. 10.1007/s00280-013-2082-4.

4. Swain SM, Kim SB, Cortés J: Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2013, 14: 461-471. 10.1016/S1470-2045(13)70130-X.

5. Polistina F, Costantin G, Febbraro A: Aggressive treatment for hepatic metastases from breast cancer: results from a single center. World J Surg. 2013, 37: 1322-1332. 10.1007/s00268-013-1986-9.

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A remarkable response to palliative treatment in metastatic breast cancer: A case report and comprehensive literature review;Radiology Case Reports;2023-12

2. No evidence of disease versus residual disease in long-term responders to first-line HER2-targeted therapy for metastatic breast cancer;British Journal of Cancer;2021-12-20

3. Long term continuous Trastuzumab use for HER2-positive advanced breast cancer;Journal of Contemporary Medical Sciences;2020-10-26

4. Complete Remission of Metastatic HER2+ Oesophagogastric Junctional Adenocarcinoma under long-term Trastuzumab Treatment;Journal of Gastrointestinal and Liver Diseases;2019-12-09

5. Treatment-free remission in CML: who, how, and why?;Hematology;2017-12-08